echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The results of the 2021 medical insurance negotiations are released, and CAR-T therapy is missed for the first time. Where is the road to protection in the future?

    The results of the 2021 medical insurance negotiations are released, and CAR-T therapy is missed for the first time. Where is the road to protection in the future?

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the end of the year, the boots landed
    .
    On December 3, 2021, the results of the annual national medical insurance negotiations were announced as scheduled: the overall success rate of the medical insurance negotiations was 80.
    34%
    .


    In this negotiation, 74 new drugs will be included in the medical insurance list: 67 were entered through negotiations, with an average price reduction of 61.
    7%, including 7 drugs for rare diseases, including noxenagen sodium; and 7 non-exclusive drugs directly included ; The renewal of 27 drugs in the catalog was successful
    .
    The price reduction rate of oncology drugs reached 64.
    88%, and the highest price reduction rate reached 93.
    97%
    .


    At a press conference held on December 3, Liu Guoen, dean of the Peking University Global Health Development Institute and leader of the pharmacoeconomics measurement expert group, concluded: "The formation of this year's national medical insurance catalogue, no matter from which point of view, All have made unprecedented progress
    .
    " What's the answer to the
     
    sky-high CAR - T therapy without medical insurance ?
     
    For Chinese patients, this medical insurance negotiation is indeed an unprecedented progress
    .
    For example, the high-priced drug treatment that has attracted much attention, the high-priced drug Noxinagen sodium for the treatment of spinal muscular atrophy (SMA) has been listed in the medical insurance catalog after many ups and downs.
    Although the price has not been announced, it is foreseeable that its base price It has been refreshed to show the firm determination of the National Medical Insurance Administration to reduce drug prices and protect the benefits of the people in the three and a half years since its establishment
    .

     
    However, for some patients, there is still a big regret in this medical insurance negotiation.
    Similar to Nosina, the sky-high anticancer drug CAR-T therapy drug called "1.
    2 million injections" failed to enter the medical insurance negotiation.
    It is believed that the absence of CAR-T this time will also leave room for further imagination in the medical insurance negotiations next year
    .

     
    CAR-T cell immunotherapy is an innovative cancer treatment after surgery, chemotherapy, and radiotherapy.
    Patients can obtain a new chance of survival and realize the possibility of a leap from cancer treatment to cure.

    .
    As one of the major breakthroughs in cancer treatment in China this year, CAR-T therapy has epoch-making significance.
    2021 will also become the first year of commercialization of cell therapy in China
    .

     
    However, while CAT-T therapy drugs bring new hope to cancer patients, they also bring new hidden worries to patients
    .
    Affected by the massive investment in research and development in the early stage, complex preparation processes, treatment principles, personalized customization and other factors, the current CAR-T therapy drugs on the market are generally priced from 1.
    2 million yuan to 1.
    29 million yuan, which is a number for most patients This is tantamount to astronomical figures, and the high medical expenses have made many patients "wow and sigh
    .
    "
     
    Entering medical insurance is an important way to solve the above-mentioned patients’ worries.
    However, for high-value drugs, entering the national medical insurance catalog is not the only way to benefit the people.
    Through the multi-level medical security system, social capital can contribute its strength and unite pharmaceutical companies with Insurance companies can benefit patients even if they have not entered the national medical insurance catalogue, and can also solve their urgent needs
    .

     
    But it is not easy to do this.
    One problem on the table is that CAR-T therapy drugs are not ordinary high-value drugs, not to mention that the two products currently on the market have just been launched in China not long ago.
    Even the price is as high as 1.
    2 million a needle.
    At such a high price, it is not easy to find a payer other than the National Medical Insurance Bureau in China
    .

     
    CAR-T therapy to enhance the availability of  magnesium believe health efforts to build outlet
    , though not easy, this phenomenon should not become feelings of health care practitioners refusal reasons and pretexts in order to improve CAR-T therapy medicines for this "difficult And the right thing", Meixin Health has been working hard to become the one who made the wind
    .

     
    In order to improve the accessibility of CAR-T therapies, Meixin Health has made many innovative and groundbreaking measures, and cooperated with insurance companies, pharmaceutical companies and hospitals to provide a package of solutions
    .

     
    For example, on October 8, the CAR-T treatment assistance program for cancer patients supported by Meixin Health United was launched
    .
    The plan has three key features: firstly, if the patient's condition progresses significantly after using CAR-T therapy for three months, he will be paid by insurance; secondly, eligible patients with difficulties can enjoy financial installments, and all installments are not required Handling fees and interest; Finally, in terms of drug benefit plans, the medical group insurance will also give patients a certain percentage of drug fee reductions, which can be directly deducted when the patients pay
    .

     
    In addition, in order to improve the accessibility of CAR-T therapy drugs, Meixin Health has recently developed a joint development with partners around the pain points of CAR-T immune cell therapy such as lack of protection, high drug costs, and complicated medical services.
    The Magisin CAR-T rights and interests service card made up for the lack of guarantee for the general public in a timely manner
    .

     
    The Magnesium CAR-T rights and interests card covers three rights, namely the rights to use CAR-T designated drugs, the rights to find drugs for special drugs at home and abroad, and the rights to apply for clinical trials
    .
    Among them, CAR-T designated drug use rights are expected to help patients solve the problem of sky-high drug costs when they need to use CAR-T therapy drugs.
    Eligible patients can obtain the current market value of 120 in China under the premise of meeting relevant requirements.
    The right to use one of the 10,000 or 1.
    29 million CAR-T drugs
    .
    Meixin Health and the two major pharmaceutical companies that currently produce CAR-T therapy drugs have established a strategic partnership, which provides a solid foundation for follow-up CAR-T therapy medical professional services
    .

     
    In addition to the above two practical actions, Meixin Health also held industry seminars with partners to discuss the joint efforts to build a multi-level CAR-T treatment protection system, improve patient accessibility, and enable patients waiting for CAR-T to be treated.
    To start, not be afraid of treatment, and to implement the vision of both companies' commitment to innovative therapies to give patients a sense of real gain
    .

     
    Helping with multi-level medical protection, Meixin Health allows more patients to use good medicine
     
    Meixin Health's action to improve the availability of CAR-T therapy drugs stems from the company's vision of building a company where everyone is guaranteed and the whole family enjoys health, so as to allow better quality medical and health services to benefit every family and help build a happier future Society
    .
    In fact, to help build a happier society in the future, the role of social enterprises is crucial
    .

     
    In accordance with the requirements of the "Opinions on Deepening the Reform of the Medical Security System" issued by the Central Committee of the Communist Party of China and the State Council, by 2030, a full-scale establishment will be completed with basic medical insurance as the main body, medical assistance as the base, supplementary medical insurance, commercial health insurance, charitable donations, and mutual medical assistance Commonly developed medical security system
    .
    In this process, the role of commercial health insurance cannot be ignored
    .
    As a supplement and extension of basic medical insurance, commercial health insurance not only effectively improves the medical security of the general public, but also plays an important role in improving the multi-level medical security system
    .

     
    As an innovative medical and health service platform, Meixin Health has accumulated a large number of medication and medical insights in the process, and adheres to the intelligent technology as the driving force, the medical and insurance dual platform as the core, to provide users and their families with more comprehensive, more economical, Better medical and health services
    .

     
    At present, Meixin Health has reached cooperation with more than 50 innovative pharmaceutical companies, and has cooperated with more than 2,000 DTP pharmacies, covering more than 400 cities across the country, benefiting more than millions of patients with tumors, chronic diseases and rare diseases, and greatly increasing patients and their The family's medical and health service experience reduces the payment pressure
    .

     
    In addition, Meixin Health has also deeply participated in the urban inclusive insurance business in major cities across the country.
    It has successively contributed to urban inclusive insurance services such as "Huhuibao", "Suhuibao", "Xihuyi Lianbao" and "Beijing Inclusive Health Insurance".
    The type of insurance project provides professional drug service support, covering more than 40 cities including Beijing, Shanghai, Hangzhou, Suzhou, etc.
    , so that more people can realize that drugs are not only "affordable" but also "available", and the health of the whole family can be best guaranteed
    .

     
    In the future, Meixin Health will continue to respond to the "Opinions on Deepening the Reform of the Medical Security System" issued by the State Council, give full play to its own advantages, solve the availability of more high-value drugs including CAR-T therapy drugs, and make every effort to help build it The multi-level medical security system contributes more to the health and happiness of the whole family of the people across the country
    .

     At the end of the year, the boots landed
    .
    On December 3, 2021, the results of the annual national medical insurance negotiations were announced as scheduled: the overall success rate of the medical insurance negotiations was 80.
    34%
    .

     
    In this negotiation, 74 new drugs will be included in the medical insurance list: 67 were entered through negotiations, with an average price reduction of 61.
    7%, including 7 drugs for rare diseases, including noxenagen sodium; and 7 non-exclusive drugs directly included ; The renewal of 27 drugs in the catalog was successful
    .
    The price reduction rate of oncology drugs reached 64.
    88%, and the highest price reduction rate reached 93.
    97%
    .

     
    At a press conference held on December 3, Liu Guoen, dean of the Peking University Global Health Development Institute and leader of the pharmacoeconomics measurement expert group, concluded: "The formation of this year's national medical insurance catalogue, no matter from which point of view, All have made unprecedented progress
    .
    " What's the answer to the
     
    sky-high CAR - T therapy without medical insurance ?
     
    For Chinese patients, this medical insurance negotiation is indeed an unprecedented progress
    .
    For example, the high-priced drug treatment that has attracted much attention, the high-priced drug Noxinagen sodium for the treatment of spinal muscular atrophy (SMA) has been listed in the medical insurance catalog after many ups and downs.
    Although the price has not been announced, it is foreseeable that its base price It has been refreshed to show the firm determination of the National Medical Insurance Administration to reduce drug prices and protect the benefits of the people in the three and a half years since its establishment
    .

     
    However, for some patients, there is still a big regret in this medical insurance negotiation.
    Similar to Nosina, the sky-high anticancer drug CAR-T therapy drug called "1.
    2 million injections" failed to enter the medical insurance negotiation.
    It is believed that the absence of CAR-T this time will also leave room for imagination in next year’s medical insurance negotiations.

    .

     
    CAR-T cell immunotherapy is an innovative cancer treatment method following surgery, chemotherapy, and radiotherapy.
    Patients can obtain a new chance of survival and realize the possibility of a leap from cancer treatment to cure
    .
    As one of the major breakthroughs in cancer treatment in China this year, CAR-T therapy has epoch-making significance.
    2021 will also become the first year of commercialization of cell therapy in China
    .

     
    However, while CAT-T therapy drugs bring new hope to cancer patients, they also bring new hidden worries to patients
    .
    Affected by the massive investment in research and development in the early stage, complex preparation processes, treatment principles, personalized customization and other factors, the current CAR-T therapy drugs on the market are generally priced from 1.
    2 million yuan to 1.
    29 million yuan, which is a number for most patients This is tantamount to astronomical figures, and the high medical expenses have made many patients "wow and sigh
    .
    "
     
    Entering medical insurance is an important way to solve the above-mentioned patients’ worries.
    However, for high-value drugs, entering the national medical insurance catalog is not the only way to benefit the people.
    Through the multi-level medical security system, social capital can contribute its strength and unite pharmaceutical companies with Insurance companies can benefit patients even if they have not entered the national medical insurance catalogue, and can also solve their urgent needs
    .

     
    But it is not easy to do this.
    One problem on the table is that CAR-T therapy drugs are not ordinary high-value drugs, not to mention that the two products currently on the market have just been launched in China not long ago.
    Even the price is as high as 1.
    2 million a needle.
    At such a high price, it is not easy to find a payer other than the National Medical Insurance Bureau in China
    .

     
    CAR-T therapy to enhance the availability of  magnesium believe health efforts to build outlet
    , though not easy, this phenomenon should not become feelings of health care practitioners refusal reasons and pretexts in order to improve CAR-T therapy medicines for this "difficult And the right thing", Meixin Health has been working hard to become the one who made the wind
    .

     
    In order to improve the accessibility of CAR-T therapies, Meixin Health has made many innovative and groundbreaking measures, and cooperated with insurance companies, pharmaceutical companies and hospitals to provide a package of solutions
    .

     
    For example, on October 8, the CAR-T treatment assistance program for cancer patients supported by Meixin Health United was launched
    .
    The plan has three key features: firstly, if the patient's condition progresses significantly after using CAR-T therapy for three months, he will be paid by insurance; secondly, eligible patients with difficulties can enjoy financial installments, and all installments are not required Handling fees and interest; Finally, in terms of drug benefit plans, the medical group insurance will also give patients a certain percentage of drug fee reductions, which can be directly deducted when the patients pay
    .

     
    In addition, in order to improve the accessibility of CAR-T therapy drugs, Meixin Health has recently developed a joint development with partners around the pain points of CAR-T immune cell therapy such as lack of protection, high drug costs, and complicated medical services.
    The Magisin CAR-T rights and interests service card made up for the lack of guarantee for the general public in a timely manner
    .

     
    The Magnesium CAR-T rights and interests card covers three rights, namely the rights to use CAR-T designated drugs, the rights to find drugs for special drugs at home and abroad, and the rights to apply for clinical trials
    .
    Among them, CAR-T designated drug use rights are expected to help patients solve the problem of sky-high drug costs when they need to use CAR-T therapy drugs.
    Eligible patients can obtain the current market value of 120 in China under the premise of meeting relevant requirements.
    The right to use one of the 10,000 or 1.
    29 million CAR-T drugs
    .
    Meixin Health and the two major pharmaceutical companies that currently produce CAR-T therapy drugs have established a strategic partnership, which provides a solid foundation for follow-up CAR-T therapy medical professional services
    .

     
    In addition to the above two practical actions, Meixin Health also held industry seminars with partners to discuss the joint efforts to build a multi-level CAR-T treatment protection system, improve patient accessibility, and enable patients waiting for CAR-T to be treated.
    To start, not be afraid of treatment, and to implement the vision of both companies' commitment to innovative therapies to give patients a sense of real gain
    .

     
    Facilitating multi-level medical protection, Magnesium Health allows more patients to use good medicines.

     
    Magnesium Health improves the availability of CAR-T therapy drugs.
    The action stems from building a company vision where everyone is guaranteed and the whole family enjoys health, so as to make better quality Our medical and health services benefit every family and help build a happier society in the future
    .
    In fact, to help build a happier society in the future, the role of social enterprises is crucial
    .

     
    In accordance with the requirements of the "Opinions on Deepening the Reform of the Medical Security System" issued by the Central Committee of the Communist Party of China and the State Council, by 2030, a full-scale establishment will be completed with basic medical insurance as the main body, medical assistance as the base, supplementary medical insurance, commercial health insurance, charitable donations, and mutual medical assistance Commonly developed medical security system
    .
    In this process, the role of commercial health insurance cannot be ignored
    .
    As a supplement and extension of basic medical insurance, commercial health insurance not only effectively improves the medical security of the general public, but also plays an important role in improving the multi-level medical security system
    .

     
    As an innovative medical and health service platform, Meixin Health has accumulated a large number of medication and medical insights in the process, and adheres to the intelligent technology as the driving force, the medical and insurance dual platform as the core, to provide users and their families with more comprehensive, more economical, Better medical and health services
    .

     
    At present, Meixin Health has reached cooperation with more than 50 innovative pharmaceutical companies, and has cooperated with more than 2,000 DTP pharmacies, covering more than 400 cities across the country, benefiting more than millions of patients with tumors, chronic diseases and rare diseases, and greatly increasing patients and their The family's medical and health service experience reduces the payment pressure
    .

     
    In addition, Meixin Health has also deeply participated in the urban inclusive insurance business in major cities across the country.
    It has successively contributed to urban inclusive insurance services such as "Huhuibao", "Suhuibao", "Xihuyi Lianbao" and "Beijing Inclusive Health Insurance".
    The type of insurance project provides professional drug service support, covering more than 40 cities including Beijing, Shanghai, Hangzhou, Suzhou, etc.
    , so that more people can realize that drugs are not only "affordable" but also "available", and the health of the whole family can be best guaranteed
    .

     
    In the future, Meixin Health will continue to respond to the "Opinions on Deepening the Reform of the Medical Security System" issued by the State Council, give full play to its own advantages, solve the availability of more high-value drugs including CAR-T therapy drugs, and make every effort to help build it The multi-level medical security system contributes more to the health and happiness of the whole family of the people across the country
    .

     





    Without medical insurance, what is the answer to the sky-high CAR - T therapy?













    Improving the accessibility of CAR-T therapy.
     Magnesium Health strives to create a wind outlet to












    help multi-level medical protection.
    Magnesium Health allows more patients to use good medicines for














    kidney and anti-aging series talks-memory loss? Nerve aging can be "stopped"!
    The "Human World" team joins hands with Meixin Health, the documentary "Revisit for the rest of my life" focuses on the road to cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.